Global Basal Cell Nevus Syndrome Drug Market

Basal Cell Nevus Syndrome Drug Comprehensive Study by Type (Itraconazole, Patidegib Hydrochloride, REM-001, TG-1042, Trifarotene, Others), Application (Clinic, Hospital, Others), Drugs (Aldara (Imiquimod), Efudex (Fluorouracil), Erivedge (Vismodegib), 5-FU (Fluorouracil), Imiquimod, Odomzo (Sonidegib)) Players and Region - Global Market Outlook to 2030

Basal Cell Nevus Syndrome Drug Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Basal Cell Nevus Syndrome Drug
Rapid growth in the technology in the past several years Basal Cell Nevus Syndrome Drug market is witnessing high demand from the end user is driving the Global Basal Cell Nevus Syndrome Drugs Market. Basal Cell Nevus Syndrome (Genetic Disorders) is also Known as Gorlin syndrome which is a condition that affects many areas of the body and increases the risk of developing various cancerous and noncancerous tumors. Symptoms include arrhythmia, medulloblastoma, ovarian fibromas, depressions in the skin, large head size and skeletal abnormalities involving the spine, ribs, or skull. Treatment includes Surgery, Radiotherapy, and Chemotherapy.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market of Global Basal Cells Nevus Syndrome Market is a fragmented market with numerous market players. Companies are still innovating with various orphan drugs. For instance, In February 2018, Adgero Biopharmaceuticals was Granted FDA Orphan Drug Designation of REM-001 Therapy for the Treatment of Basal Cell Carcinoma Nevus Syndrome. In a Phase 1/2 clinical trial (CA001B), 14 patients with BCCNS were enrolled and treated with REM-001 Therapy. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Basal Cell Nevus Syndrome Drug market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Adgero Biopharmaceuticals Holdings Inc (United States), Galderma Medical Solutions (Switzerland), Mayne Pharma Group Ltd. (United States), PellePharm Inc. (United States), Transgene S.A. (France), Biofrontera AG (Germany), Biosceptre International Ltd (Australia), BLR Bio LLC (United States), Genextra Spa (Italy) and Laboratories Ojer Pharma SL (Spain) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Redx Pharma (United Kingdom), Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (China), Regeneron Pharmaceuticals Inc (United States) and Roche Holdings Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Basal Cell Nevus Syndrome Drug market by Type (Itraconazole, Patidegib Hydrochloride, REM-001, TG-1042, Trifarotene and Others), Application (Clinic, Hospital and Others) and Region.



On the basis of geography, the market of Basal Cell Nevus Syndrome Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. Aldara (Imiquimod) will boost the Basal Cell Nevus Syndrome Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing risk of developing various cancerous and noncancerous tumors among patients.

Market Growth Drivers:
Increased R & D in the Gorlin Syndrome Treatment, Growing Prevalence of Infectious Diseases like Cancer and Supportive Government investment in the treatment of Basal Cell Nevus Drugs Market

Challenges:
More and more research and clinical trials are still required for the treatment of Basal Cell Nevus Syndrome as the disease still lacks proper treatment.

Restraints:
Very few available therapies for the Basal Cell Nevus Syndrome and many patients lack treatment option, thereby hindering the Growth of the market

Opportunities:
Clinical trials conducted by the researchers in the field of Basal Cell Nevus Syndrome Drugs Treatment is providing an opportunity for the market.

Market Leaders and their expansionary development strategies
On December 12, 2023, Mirati announced the FDA approval of KRYASTREX (mirvetuximab soravumab) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation. While not specifically for BCNS, this approval represents a significant advancement in targeted therapies for patients with KRAS mutations, which are also relevant to BCNS.
On November 17, 2023, Syndax announced the initiation of a Phase 2b clinical trial evaluating Entrectinib for the treatment of patients with Gorlin syndrome-associated tumors, including basal cell carcinomas (BCCs). This trial holds promise for BCNS patients as Entrectinib targets the MAPK pathway, which is frequently mutated in BCNS.
In March 2018, Orphan Designation medicines (EU/3/18/1998) was Granted By The European Commission To Blue-Reg Europe, France, For Patidegib Hydrochloride (A First-In-Class Topical Hedgehog Pathway Inhibitor) for the Treatment of Basal Cell Nevus Syndrome.

Key Target Audience
Basal Cell Nevus Syndrome Drug Manufacturers, Pharmaceutical Companies, Traders/Distributors/Wholesalers/Retailers, Downstream Vendors, Potential Investors and Government & Regulatory Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Itraconazole
  • Patidegib Hydrochloride
  • REM-001
  • TG-1042
  • Trifarotene
  • Others
By Application
  • Clinic
  • Hospital
  • Others
By Drugs
  • Aldara (Imiquimod)
  • Efudex (Fluorouracil)
  • Erivedge (Vismodegib)
  • 5-FU (Fluorouracil)
  • Imiquimod
  • Odomzo (Sonidegib)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased R & D in the Gorlin Syndrome Treatment
      • 3.2.2. Growing Prevalence of Infectious Diseases like Cancer
      • 3.2.3. Supportive Government investment in the treatment of Basal Cell Nevus Drugs Market
    • 3.3. Market Challenges
      • 3.3.1. More and more research and clinical trials are still required for the treatment of Basal Cell Nevus Syndrome as the disease still lacks proper treatment.
    • 3.4. Market Trends
      • 3.4.1. Increasing risk of developing various cancerous and noncancerous tumors among patients.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Basal Cell Nevus Syndrome Drug, by Type, Application, Drugs and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Basal Cell Nevus Syndrome Drug (Volume)
      • 5.2.1. Global Basal Cell Nevus Syndrome Drug by: Type (Volume)
        • 5.2.1.1. Itraconazole
        • 5.2.1.2. Patidegib Hydrochloride
        • 5.2.1.3. REM-001
        • 5.2.1.4. TG-1042
        • 5.2.1.5. Trifarotene
        • 5.2.1.6. Others
      • 5.2.2. Global Basal Cell Nevus Syndrome Drug by: Application (Volume)
        • 5.2.2.1. Clinic
        • 5.2.2.2. Hospital
        • 5.2.2.3. Others
      • 5.2.3. Global Basal Cell Nevus Syndrome Drug by: Drugs (Volume)
        • 5.2.3.1. Aldara (Imiquimod)
        • 5.2.3.2. Efudex (Fluorouracil)
        • 5.2.3.3. Erivedge (Vismodegib)
        • 5.2.3.4. 5-FU (Fluorouracil)
        • 5.2.3.5. Imiquimod
        • 5.2.3.6. Odomzo (Sonidegib)
      • 5.2.4. Global Basal Cell Nevus Syndrome Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Basal Cell Nevus Syndrome Drug (Price)
      • 5.3.1. Global Basal Cell Nevus Syndrome Drug by: Type (Price)
  • 6. Basal Cell Nevus Syndrome Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Adgero Biopharmaceuticals Holdings Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Galderma Medical Solutions (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mayne Pharma Group Ltd. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. PellePharm Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Transgene S.A. (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biofrontera AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biosceptre International Ltd (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. BLR Bio LLC (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Genextra Spa (Italy)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Laboratories Ojer Pharma SL (Spain)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Basal Cell Nevus Syndrome Drug Sale, by Type, Application, Drugs and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Basal Cell Nevus Syndrome Drug (Volume)
      • 7.2.1. Global Basal Cell Nevus Syndrome Drug by: Type (Volume)
        • 7.2.1.1. Itraconazole
        • 7.2.1.2. Patidegib Hydrochloride
        • 7.2.1.3. REM-001
        • 7.2.1.4. TG-1042
        • 7.2.1.5. Trifarotene
        • 7.2.1.6. Others
      • 7.2.2. Global Basal Cell Nevus Syndrome Drug by: Application (Volume)
        • 7.2.2.1. Clinic
        • 7.2.2.2. Hospital
        • 7.2.2.3. Others
      • 7.2.3. Global Basal Cell Nevus Syndrome Drug by: Drugs (Volume)
        • 7.2.3.1. Aldara (Imiquimod)
        • 7.2.3.2. Efudex (Fluorouracil)
        • 7.2.3.3. Erivedge (Vismodegib)
        • 7.2.3.4. 5-FU (Fluorouracil)
        • 7.2.3.5. Imiquimod
        • 7.2.3.6. Odomzo (Sonidegib)
      • 7.2.4. Global Basal Cell Nevus Syndrome Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Basal Cell Nevus Syndrome Drug (Price)
      • 7.3.1. Global Basal Cell Nevus Syndrome Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Basal Cell Nevus Syndrome Drug Sales: by Type(K Units)
  • Table 2. Basal Cell Nevus Syndrome Drug Sales Itraconazole , by Region K Units (2018-2023)
  • Table 3. Basal Cell Nevus Syndrome Drug Sales Patidegib Hydrochloride , by Region K Units (2018-2023)
  • Table 4. Basal Cell Nevus Syndrome Drug Sales REM-001 , by Region K Units (2018-2023)
  • Table 5. Basal Cell Nevus Syndrome Drug Sales TG-1042 , by Region K Units (2018-2023)
  • Table 6. Basal Cell Nevus Syndrome Drug Sales Trifarotene , by Region K Units (2018-2023)
  • Table 7. Basal Cell Nevus Syndrome Drug Sales Others , by Region K Units (2018-2023)
  • Table 8. Basal Cell Nevus Syndrome Drug Sales: by Application(K Units)
  • Table 9. Basal Cell Nevus Syndrome Drug Sales Clinic , by Region K Units (2018-2023)
  • Table 10. Basal Cell Nevus Syndrome Drug Sales Hospital , by Region K Units (2018-2023)
  • Table 11. Basal Cell Nevus Syndrome Drug Sales Others , by Region K Units (2018-2023)
  • Table 12. Basal Cell Nevus Syndrome Drug Sales: by Drugs(K Units)
  • Table 13. Basal Cell Nevus Syndrome Drug Sales Aldara (Imiquimod) , by Region K Units (2018-2023)
  • Table 14. Basal Cell Nevus Syndrome Drug Sales Efudex (Fluorouracil) , by Region K Units (2018-2023)
  • Table 15. Basal Cell Nevus Syndrome Drug Sales Erivedge (Vismodegib) , by Region K Units (2018-2023)
  • Table 16. Basal Cell Nevus Syndrome Drug Sales 5-FU (Fluorouracil) , by Region K Units (2018-2023)
  • Table 17. Basal Cell Nevus Syndrome Drug Sales Imiquimod , by Region K Units (2018-2023)
  • Table 18. Basal Cell Nevus Syndrome Drug Sales Odomzo (Sonidegib) , by Region K Units (2018-2023)
  • Table 19. South America Basal Cell Nevus Syndrome Drug Sales, by Country K Units (2018-2023)
  • Table 20. South America Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 21. South America Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 22. South America Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 23. Brazil Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 24. Brazil Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 25. Brazil Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 26. Argentina Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 27. Argentina Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 28. Argentina Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 29. Rest of South America Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 30. Rest of South America Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 31. Rest of South America Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 32. Asia Pacific Basal Cell Nevus Syndrome Drug Sales, by Country K Units (2018-2023)
  • Table 33. Asia Pacific Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 34. Asia Pacific Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 35. Asia Pacific Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 36. China Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 37. China Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 38. China Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 39. Japan Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 40. Japan Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 41. Japan Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 42. India Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 43. India Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 44. India Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 45. South Korea Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 46. South Korea Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 47. South Korea Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 48. Taiwan Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 49. Taiwan Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 50. Taiwan Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 51. Australia Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 52. Australia Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 53. Australia Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 54. Rest of Asia-Pacific Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 55. Rest of Asia-Pacific Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 56. Rest of Asia-Pacific Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 57. Europe Basal Cell Nevus Syndrome Drug Sales, by Country K Units (2018-2023)
  • Table 58. Europe Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 59. Europe Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 60. Europe Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 61. Germany Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 62. Germany Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 63. Germany Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 64. France Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 65. France Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 66. France Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 67. Italy Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 68. Italy Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 69. Italy Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 70. United Kingdom Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 71. United Kingdom Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 72. United Kingdom Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 73. Netherlands Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 74. Netherlands Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 75. Netherlands Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 76. Rest of Europe Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 77. Rest of Europe Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 78. Rest of Europe Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 79. MEA Basal Cell Nevus Syndrome Drug Sales, by Country K Units (2018-2023)
  • Table 80. MEA Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 81. MEA Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 82. MEA Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 83. Middle East Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 84. Middle East Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 85. Middle East Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 86. Africa Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 87. Africa Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 88. Africa Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 89. North America Basal Cell Nevus Syndrome Drug Sales, by Country K Units (2018-2023)
  • Table 90. North America Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 91. North America Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 92. North America Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 93. United States Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 94. United States Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 95. United States Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 96. Canada Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 97. Canada Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 98. Canada Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 99. Mexico Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2018-2023)
  • Table 100. Mexico Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2018-2023)
  • Table 101. Mexico Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2018-2023)
  • Table 102. Basal Cell Nevus Syndrome Drug: by Type(USD/Units)
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Basal Cell Nevus Syndrome Drug Sales: by Type(K Units)
  • Table 114. Basal Cell Nevus Syndrome Drug Sales Itraconazole , by Region K Units (2025-2030)
  • Table 115. Basal Cell Nevus Syndrome Drug Sales Patidegib Hydrochloride , by Region K Units (2025-2030)
  • Table 116. Basal Cell Nevus Syndrome Drug Sales REM-001 , by Region K Units (2025-2030)
  • Table 117. Basal Cell Nevus Syndrome Drug Sales TG-1042 , by Region K Units (2025-2030)
  • Table 118. Basal Cell Nevus Syndrome Drug Sales Trifarotene , by Region K Units (2025-2030)
  • Table 119. Basal Cell Nevus Syndrome Drug Sales Others , by Region K Units (2025-2030)
  • Table 120. Basal Cell Nevus Syndrome Drug Sales: by Application(K Units)
  • Table 121. Basal Cell Nevus Syndrome Drug Sales Clinic , by Region K Units (2025-2030)
  • Table 122. Basal Cell Nevus Syndrome Drug Sales Hospital , by Region K Units (2025-2030)
  • Table 123. Basal Cell Nevus Syndrome Drug Sales Others , by Region K Units (2025-2030)
  • Table 124. Basal Cell Nevus Syndrome Drug Sales: by Drugs(K Units)
  • Table 125. Basal Cell Nevus Syndrome Drug Sales Aldara (Imiquimod) , by Region K Units (2025-2030)
  • Table 126. Basal Cell Nevus Syndrome Drug Sales Efudex (Fluorouracil) , by Region K Units (2025-2030)
  • Table 127. Basal Cell Nevus Syndrome Drug Sales Erivedge (Vismodegib) , by Region K Units (2025-2030)
  • Table 128. Basal Cell Nevus Syndrome Drug Sales 5-FU (Fluorouracil) , by Region K Units (2025-2030)
  • Table 129. Basal Cell Nevus Syndrome Drug Sales Imiquimod , by Region K Units (2025-2030)
  • Table 130. Basal Cell Nevus Syndrome Drug Sales Odomzo (Sonidegib) , by Region K Units (2025-2030)
  • Table 131. South America Basal Cell Nevus Syndrome Drug Sales, by Country K Units (2025-2030)
  • Table 132. South America Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 133. South America Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 134. South America Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 135. Brazil Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 136. Brazil Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 137. Brazil Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 138. Argentina Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 139. Argentina Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 140. Argentina Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 141. Rest of South America Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 142. Rest of South America Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 143. Rest of South America Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 144. Asia Pacific Basal Cell Nevus Syndrome Drug Sales, by Country K Units (2025-2030)
  • Table 145. Asia Pacific Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 146. Asia Pacific Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 147. Asia Pacific Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 148. China Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 149. China Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 150. China Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 151. Japan Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 152. Japan Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 153. Japan Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 154. India Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 155. India Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 156. India Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 157. South Korea Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 158. South Korea Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 159. South Korea Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 160. Taiwan Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 161. Taiwan Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 162. Taiwan Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 163. Australia Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 164. Australia Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 165. Australia Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 166. Rest of Asia-Pacific Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 167. Rest of Asia-Pacific Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 168. Rest of Asia-Pacific Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 169. Europe Basal Cell Nevus Syndrome Drug Sales, by Country K Units (2025-2030)
  • Table 170. Europe Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 171. Europe Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 172. Europe Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 173. Germany Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 174. Germany Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 175. Germany Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 176. France Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 177. France Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 178. France Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 179. Italy Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 180. Italy Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 181. Italy Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 182. United Kingdom Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 183. United Kingdom Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 184. United Kingdom Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 185. Netherlands Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 186. Netherlands Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 187. Netherlands Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 188. Rest of Europe Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 189. Rest of Europe Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 190. Rest of Europe Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 191. MEA Basal Cell Nevus Syndrome Drug Sales, by Country K Units (2025-2030)
  • Table 192. MEA Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 193. MEA Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 194. MEA Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 195. Middle East Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 196. Middle East Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 197. Middle East Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 198. Africa Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 199. Africa Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 200. Africa Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 201. North America Basal Cell Nevus Syndrome Drug Sales, by Country K Units (2025-2030)
  • Table 202. North America Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 203. North America Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 204. North America Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 205. United States Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 206. United States Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 207. United States Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 208. Canada Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 209. Canada Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 210. Canada Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 211. Mexico Basal Cell Nevus Syndrome Drug Sales, by Type K Units (2025-2030)
  • Table 212. Mexico Basal Cell Nevus Syndrome Drug Sales, by Application K Units (2025-2030)
  • Table 213. Mexico Basal Cell Nevus Syndrome Drug Sales, by Drugs K Units (2025-2030)
  • Table 214. Basal Cell Nevus Syndrome Drug: by Type(USD/Units)
  • Table 215. Research Programs/Design for This Report
  • Table 216. Key Data Information from Secondary Sources
  • Table 217. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Basal Cell Nevus Syndrome Drug: by Type K Units (2018-2023)
  • Figure 5. Global Basal Cell Nevus Syndrome Drug: by Application K Units (2018-2023)
  • Figure 6. Global Basal Cell Nevus Syndrome Drug: by Drugs K Units (2018-2023)
  • Figure 7. South America Basal Cell Nevus Syndrome Drug Share (%), by Country
  • Figure 8. Asia Pacific Basal Cell Nevus Syndrome Drug Share (%), by Country
  • Figure 9. Europe Basal Cell Nevus Syndrome Drug Share (%), by Country
  • Figure 10. MEA Basal Cell Nevus Syndrome Drug Share (%), by Country
  • Figure 11. North America Basal Cell Nevus Syndrome Drug Share (%), by Country
  • Figure 12. Global Basal Cell Nevus Syndrome Drug: by Type USD/Units (2018-2023)
  • Figure 13. Global Basal Cell Nevus Syndrome Drug share by Players 2023 (%)
  • Figure 14. Global Basal Cell Nevus Syndrome Drug share by Players (Top 3) 2023(%)
  • Figure 15. Global Basal Cell Nevus Syndrome Drug share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Adgero Biopharmaceuticals Holdings Inc (United States) Revenue, Net Income and Gross profit
  • Figure 18. Adgero Biopharmaceuticals Holdings Inc (United States) Revenue: by Geography 2023
  • Figure 19. Galderma Medical Solutions (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Galderma Medical Solutions (Switzerland) Revenue: by Geography 2023
  • Figure 21. Mayne Pharma Group Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Mayne Pharma Group Ltd. (United States) Revenue: by Geography 2023
  • Figure 23. PellePharm Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. PellePharm Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Transgene S.A. (France) Revenue, Net Income and Gross profit
  • Figure 26. Transgene S.A. (France) Revenue: by Geography 2023
  • Figure 27. Biofrontera AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Biofrontera AG (Germany) Revenue: by Geography 2023
  • Figure 29. Biosceptre International Ltd (Australia) Revenue, Net Income and Gross profit
  • Figure 30. Biosceptre International Ltd (Australia) Revenue: by Geography 2023
  • Figure 31. BLR Bio LLC (United States) Revenue, Net Income and Gross profit
  • Figure 32. BLR Bio LLC (United States) Revenue: by Geography 2023
  • Figure 33. Genextra Spa (Italy) Revenue, Net Income and Gross profit
  • Figure 34. Genextra Spa (Italy) Revenue: by Geography 2023
  • Figure 35. Laboratories Ojer Pharma SL (Spain) Revenue, Net Income and Gross profit
  • Figure 36. Laboratories Ojer Pharma SL (Spain) Revenue: by Geography 2023
  • Figure 37. Global Basal Cell Nevus Syndrome Drug: by Type K Units (2025-2030)
  • Figure 38. Global Basal Cell Nevus Syndrome Drug: by Application K Units (2025-2030)
  • Figure 39. Global Basal Cell Nevus Syndrome Drug: by Drugs K Units (2025-2030)
  • Figure 40. South America Basal Cell Nevus Syndrome Drug Share (%), by Country
  • Figure 41. Asia Pacific Basal Cell Nevus Syndrome Drug Share (%), by Country
  • Figure 42. Europe Basal Cell Nevus Syndrome Drug Share (%), by Country
  • Figure 43. MEA Basal Cell Nevus Syndrome Drug Share (%), by Country
  • Figure 44. North America Basal Cell Nevus Syndrome Drug Share (%), by Country
  • Figure 45. Global Basal Cell Nevus Syndrome Drug: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Adgero Biopharmaceuticals Holdings Inc (United States)
  • Galderma Medical Solutions (Switzerland)
  • Mayne Pharma Group Ltd. (United States)
  • PellePharm Inc. (United States)
  • Transgene S.A. (France)
  • Biofrontera AG (Germany)
  • Biosceptre International Ltd (Australia)
  • BLR Bio LLC (United States)
  • Genextra Spa (Italy)
  • Laboratories Ojer Pharma SL (Spain)
Additional players considered in the study are as follows:
Redx Pharma (United Kingdom) , Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (China) , Regeneron Pharmaceuticals Inc (United States) , Roche Holdings Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 208 Pages 80 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Basal Cell Nevus Syndrome Drug Market Quantitative research analysis
Global Basal Cell Nevus Syndrome Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Adgero Biopharmaceuticals Holdings Inc (United States), Galderma Medical Solutions (Switzerland), Mayne Pharma Group Ltd. (United States), PellePharm Inc. (United States), Transgene S.A. (France), Biofrontera AG (Germany), Biosceptre International Ltd (Australia), BLR Bio LLC (United States), Genextra Spa (Italy) and Laboratories Ojer Pharma SL (Spain) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing risk of developing various cancerous and noncancerous tumors among patients." is seen as one of major influencing trends for Basal Cell Nevus Syndrome Drug Market during projected period 2023-2030.
The Basal Cell Nevus Syndrome Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Basal Cell Nevus Syndrome Drug Market Report?

Have a Query? Click Here

Other Related Reports

Autoimmune Disease Diagnosis Comprehensive Study by Type (Rheumatoid arthritis, Lupus, Coeliac disease, Type 1 diabetes, Others), End Users (Hospitals, Clinics, Pharmaceutical Companies, Government R...
$ 3750
Mycoplasma Testing Comprehensive Study by Type (Instruments, Kits & Reagents (Elimination Kits & Reagent, Standards & Controls, PCR Assay, Stains, Nucleic Acid Detection, Other), Services), Applicati...
$ 3750
Bracing and Supports Comprehensive Study by Type (Knee Braces & Supports, Foot and Ankle Braces & Supports, Spinal Orthoses, Upper Extremity Braces & Supports), Application (Ligament Injury, Preventi...
$ 3650
Endodontics Treatments Comprehensive Study by Type (Root Canal Therapy, Fixing Broken Teeth, Dental Trauma), Application (Hospitals, Dental Clinic, Laboratories, Dental Academic Research Institute), ...
$ 3750
Blood Irradiation Comprehensive Study by Type (X-ray Blood Irradiation, Gamma-ray Blood Irradiation), Application (Patients Inherited Immune System Disorder, Patients with Hodgkin’s Disease, Others),...
$ 3450
Zika Virus Testing Comprehensive Study by Technology (Molecular Test, Serologic Test, Plaque Reduction Neutralization Test (PRNT)), End User (Hospital/Clinic, Diagnostics Laboratory, Academic and Res...
$ 3350